CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (Nasdaq: TENK) is a post-merger oncology company that reached the public markets through a business combination with TenX Keane Acquisition Corp, a blank-check company sponsored by TenX Keane LLC that completed its IPO in 2021. The company filed a Form 424B3 prospectus supplement with the SEC on May 6, 2026, under accession number 0001213900-26-052840, relating to the resale of registered securities. Citius Oncology operates in the healthcare sector with a focus on oncology therapeutics, having been spun out from Citius Pharmaceuticals as part of the de-SPAC transaction. Sign up at SpacDesk for full data and analytics on TENK and every SPAC filing in the market.